Cost-Effectiveness of Screening Mammography Beyond Age 75 Years : A Cost-Effectiveness Analysis.

ABSTRACT:

Background

The cost-effectiveness of screening mammography beyond age 75 years remains unclear.

Objective

To estimate benefits, harms, and cost-effectiveness of extending mammography to age 80, 85, or 90 years according to comorbidity burden.

Design

Markov microsimulation model.

Data sources

SEER (Surveillance, Epidemiology, and End Results) program and Breast Cancer Surveillance Consortium.

Target population

U.S. women aged 65 to 90 years in groups defined by Charlson comorbidity score (CCS).

Time horizon

Lifetime.

Perspective

National health payer.

Intervention

Screening mammography to age 75, 80, 85, or 90 years.

Outcome measures

Breast cancer death, survival, and costs.

Results of base-case analysis

Extending bienni

SUBMITTER: Schousboe JT 

PROVIDER: S-EPMC9621600 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature